This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Last week, we examined the growing concentration of specialty drug dispensing revenues among the largest pharmacies. See The Top 15 Specialty Pharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market. Drawing from DCIs new 2025 Economic Report on U.S. Today, we dive deeper. All rights reserved.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: Whats Next for Retail Pharmacy: Data, Debate, and Disruption This event will be broadcast live on: Friday, June 20, 2025 12:00 p.m. It is part of The Drug Channels 2025 Video Webinar Series.
This unique, new event will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. The Leadership Forum will be an executive gathering where drug channel leaders can network and discuss key issues and challenges facing the commercial healthcare system.
I am pleased to announce that Drug Channels Institutes new 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers is now available for purchase and immediate download. Pharmacies and Pharmacy Benefit Managers. 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.
Multimodal language models Generative AI models (GenAI) in the pharmaceutical field have reached the highest level of attention with the Nobel Prizes to Demis Hassabis and John Jumper for AlphaFold, which can predict protein structures. The Rise of Multimodal Language Models in Drug Development (2025).
This week, Im rerunning some popular posts while I prepare for tomorrows Drug Channels Outlook 2025 live video webinar. However, provider pushback has limited specialty pharmacies' share gains, so that buy-and-bill remains the most common channel for these products. Click here to see the original post from September 2024.
Informa Connect’s Trade and Channel Strategies December 10-12, 2024 at the W Hotel in Philadelphia, PA Drug Channels readers save 10% with code 24DC10 * Pharmacy and distribution models are growing increasingly complex. Is my organization haemorrhaging money to stay afloat with the shift to alternative distribution and pharmacy models?
In todays fast-moving pharmaceutical marketplace, insight is everything. Why Professionals Choose DCI eLearning These modules were built from the ground up for pharmaceutical professionalsfrom seasoned experts to newcomers looking to understand the industry's complex web of relationships. pharmaceutical distribution.
Global Pharmaceutical Contract Sales Outsourcing Market to Reach $24.8 Billion by 2030: Strategic Insights, Regional Trends, and Technological Shifts Reshaping the Landscape The global pharmaceutical contract sales outsourcing (CSO) market is entering a transformative phase, with its value expected to grow from $17.3
This week, Im rerunning some popular posts while I prepare for Fridays Drug Channels Outlook 2025 live video webinar. As you reread the article below, note that some manufacturers have already announced wholesale acquisition cost (WAC) list price declines for 2025. Pharmacies and Pharmacy Benefit Managers.
This exclusive event will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. Registered attendees include senior executives from pharmaceutical manufacturers, pharmacy benefit managers, health systems, physician practices, pharmacies, wholesalers, and more. drug channels. I hope you can join us!
Jeanine Robertson, Director of Pharmacy Network Relations, Liviniti WHAT TO EXPECT Expect bold, candid discussionsnot just presentations. Jason Dombi, Senior Vice President of Strategic Solutions, Cencora WATCH HIGHLIGHTS FROM DCLF 2025 Relive the #DCLF2025 energy and hear testimonials directly from participants. Click here.
My goal is not only to tell the story of a pharmaceutical staple but to share what my decades-long work in evidence synthesis in epidemiology has taught me about researching scientific history. I could not find, that it hath, or ever had, any place in pharmacy, or any fuch qualities, as I fufpected afcribed to it by the botanifts.
To help control impurities, the FDA requires all starting materials used in drug manufacturing and final pharmaceutical products to be evaluated for “identity, strength, quality and purity.” USP posted a notice of intent to omit these monographs, with a targeted official date of August 1, 2025.
On November 17th, CMS issued its final guidance on the Discount Program in which it responded to public comments and provided updated guidance for the Discount Program for 2025 and 2026. Manufacturers must sign the agreement by March 1, 2024, to participate in the 2025 plan year. state pharmaceutical assistance programs).
Consultants CornerReflections from a Study Monitor and Director: A Career in Toxicology, by Bill Brock pmjackson Fri, 05/16/2025 - 18:40 Some might say a reflective piece like this could come across as sounding preachy. This article was published in May 2025. Maybe it is. Image Guest Bloggers_William Brock_Thumbnail_0.png
The Agenda also includes several long-term actions expected to take place in 2024 and 2025 – included as part of FDA’s long-term regulatory agenda. The rule, will also, if finalized, address communication with State boards of pharmacy. The anticipated date of publication is June 2023, meaning we should see this regulation imminently.
WUSF / AgencyIQ November 1 Initial deadline for NDSRIs Under a 2023 guidance document, the FDA has recommended that pharmaceutical companies assess Nitrosamine Drug-Related Substance Impurities for their products by November 1, 2023, with confirmatory testing due by August 1, 2025.
CDER, CBER Draft 12/29/2025 FDA must issue final guidance no later than 18 months after the close of the public comment period for draft guidance. use of RWE, registries) for capturing post-approval safety and efficacy data for cell and gene therapy products.
Recently Recursion Pharmaceuticals unbiased, machine learning-powered genomics screen rapidly identified and advanced REC-1245. About the authors Remco Jan Geukes Foppen , PhD, is an AI and life sciences expert specialising in the pharmaceutical sector. This is an AI-generated image.
Surveys (eg, 2024 State of Tech in Biopharma Report ) predict a doubling of R&D data year-over-year in 2025, highlighting the continued growth of available data. This article, along with other insightful analyses, will be featured in our upcoming report, Beyond the Lab – Artificial Intelligence, launching on 21st March 2025.
Wasserstein We are still parsing through the May 12 Executive Order (EO), Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients and impacts this may have on the pharmaceutical industry. Weve blogged about Most-Favored-Nation (MFN) drug pricing and how the new EO goes well beyond the 2020 order and questions we have.
Published June 12, 2025 Amy Baxter Staff Reporter post share post print email license Win McNamee via Getty Images First published on The budget bill currently under consideration in Congress is big — and it’s complicated. By Jacob Bell • May 6, 2025 Keep up with the story. But the bill’s path forward is uncertain.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content